A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

← catalyst calendar

NCT04590326 · readout in 218 d

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

612estimated

Sites

Countries

Belgium, France, Spain +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-12-08

actual

When the study began enrolling

Primary completion

2027-03-25

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-11-30

estimated

The whole study's end, after follow-up

First posted

2020-10-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-11-21

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Endometrial Cancer

Interventions

Drug: REGN5668
Drug: Cemiplimab — also filed as REGN2810, Libtayo®
Drug: Ubamatamab — also filed as REGN4018
Drug: Sarilumab — also filed as Kevzara®
Drug: Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

Primary outcomes

what the primary-completion date above is the date OF

Incidence of Dose Limiting Toxicities (DLT)

measured 42 days

Incidence of DLTs

measured 21 days post combination administration

Incidence of Treatment-Emergent Adverse Events (TEAEs)